SBS is a chronic and severe condition, characterized
by malabsorption, and
many patients require
long-term PS1-3

Patients with SHORT BOWEL SYNDROME
SYNDROME suffer from
irreparable GI damage and
functional deficiency of
the intestine1,4

Many patients with SBS have had a substantial section of their small intestine removed. In some patients, the colon or large intestine may also be removed1,3,5
Patients experience impaired intestinal absorption of macronutrients, micronutrients, electrolytes, and fluids6
Many patients with SBS require long-term PS to maintain nutrition, hydration, clinical status, and survival1,5

As of 2021, there are ~12,000 patients in
the United States with SBS who are dependent on PS7

77% were Caucasian, 16% Black, and 6% other
Majority were female (66%)
70% of patients were adults 18-64 years of age, and patients 3-17 years of age made up the other 30%

Surgical complications are the leading
causes of SBS in adults8

Main causes of SBS in adults
0
%-
0
%
Surgical complications
0
%-
0
%
Mesenteric infarctions
0
%-
0
%
Crohn’s disease
0
%
Neoplasms
0
%
Radiation enteritis
0
%-
0
%
Abdominal trauma

Remnant bowel anatomy is an important clinical factor
for patients with SBS5

Patients with SBS can be categorized into 3 groups based on remnant anatomy5,8:
Type 1
End-jejunostomy
Complete resection of ileum and colon. The jejunum is preserved.
Type 2
Jejuno-colonic anastomosis
Resection of most of the ileum. A portion of the colon is preserved.
Type 3
Jejuno-ileal anastomosis
Retains colon and ileocecal valve with a portion of terminal ileum and jejunum.


SURGICAL RESECTION of the
intestine leads to loss of:

Absorptive surface area6
Loss of absorptive surface area, causing malabsorption of nutrients, electrolytes and water.
Insufficient intestinal absorptive function6,9
Intestine fails to absorb amino acids and small peptides, which are resources for protein synthesis and energy.
Endocrine cells and GI peptides6
Peptide deficiency (ie, GLP-1 and GLP-2) leads to rapid gastric emptying, shortened intestinal transit, and hypergastrinemia.
Ileocecal valve3,6,8
Dysregulation leads to bacterial overgrowth, malabsorption of fat and vitamin B12, bile salt deconjugation, fluid loss, and liver injury.

Symptoms of SBS are an everyday concern
for patients3

According to an independent analysis, 50% of patients reported
they have an accident or leak at least once per week.10

Frequency of accidents or leaks reported by patients with SBS10:

PIE CHART HERE

Signs, symptoms, and potential complications of SBS include3,11:

  • Malnutrition
  • Weight loss
  • Drowsiness
  • Apathy
  • Low body temperature
  • Diarrhea
  • Confusion
  • D-lactic acidosis
  • Weakness
  • Depression
  • Impaired growth and sexual development
  • Dehydration
  • Difficulty concentrating
  • Irritability
  • Premature aging
Diarrhea is the most debilitating symptom of SBS for many patients12

Nutritional, pharmacologic, and surgical
interventions have different roles in managing SBS5,12

Nutritional5,12

  • PS provides the essential nutrients and fluids
  • Diet modification includes specialized dietary guidance aimed at improving absorption of oral calories and liquid

Pharmacologic8,12,13

Symptomatic management

  • Antidiarrheals
  • Antisecretory agents (H2 blockers, PPIs)
  • Bile acid binders
  • Antibiotics
  • Pancreatic enzyme replacement therapy
  • Lactase

Targeted therapy

  • GLP-2 analogs

Surgical14

  • Intestinal lengthening procedures
  • Intestinal tapering
  • Intestinal transplantation

Some patients with SBS require LONG-TERM PS to receive
fluids and nutrients necessary for their survival15

According to a survey, patients with SBS
spend significant time receiving PS4
12.4
hours per day (range: 9-18 hours)
6
days per week (range: 3-7 days)
Animated GIF
You could walk across the Golden Gate
Bridge and back 18½ times
in the time it takes the average patient with SBS to receive their PS every day.4
Animated GIF
You could cover the length of a football field with the 312 PS bags used by the average patient with SBS in one year16

Patients with SBS dependent on PS may experience17

  • Catheter-related infections
  • IFALD
  • Metabolic bone disease
  • Thrombosis
  • Impaired sleep
  • Fatigue
  • Depression
  • Body image issues
  • Disrupted social activities*
  • Strain on relationships with family, friends, partners*

*As reported by family.17

Although life-saving, PS can lead to life-threatening complications such as catheter-related bloodstream infections, venous thrombosis, metabolic bone disease, and liver disease.15,17

Sleep disturbances are
Commonly reported by
patients with SBS who are receiving PS4

According to a survey, 2 OUT OF 3 PATIENTS WITH SBS WHO ARE DEPENDENT ON PS

report disturbed sleep as a result of their treatment

The prolonged use of
PS can lead to liver
disease18

26%of patients
develop liver disease after 2 years of PS

PS is supportive management and therefore does not treat insufficient absorptive capacity, which is the underlying issue for patients with SBS who are dependent on PS.3

SBS management
goals include12:

  • Decreasing the severity of SBS symptoms
  • Minimizing complications associated with SBS
  • Reducing long-term PS dependency
GI=gastrointestinal; GLP=glucagon-like peptide; IFALD=intestinal failure-associated liver disease; PPI=protein pump inhibitor; PS=parenteral support; SBS=short bowel syndrome.
REFERENCES

1. Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. 2015;34(2):171-180. doi:10.1016/j.clnu.2014.08.017

2. Belcher E, Mercer D, Raphael BP, Salinas GD, Stacy S, Tappenden KA. Management of short-bowel syndrome: a survey of unmet educational needs among healthcare providers. JPEN J Parenter Enteral Nutr. 2022;46(8):1839-1846. doi:10.1002/jpen.2388

3. Jeppesen PB. Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure. JPEN J Parenter Enteral Nutr. 2014;38(suppl 1):S8-S13. doi:10.1177/0148607114520994

4. Data on file. Qualitative interviews of patients with short bowel syndrome and healthcare providers.

5. Iyer K, DiBaise JK, Rubio-Tapia A. AGA clinical practice update on management of short bowel syndrome: expert review. Clin Gastroenterol Hepatol. 2022;20(10):2185-2194.e2. doi:10.1016/j.cgh.2022.05.032

6. Seetharam P, Rodrigues G. Short bowel syndrome: a review of management options. Saudi J Gastroenterol. 2011;17(4):229-235. doi:10.4103/1319-3767.82573

7. Ali A, Mitchell G, Gallivan M, Henderson J, Yang M, Iyer K. Epidemiology of patients with short bowel syndrome with intestinal failure (SBS-IF) in the US—findings using real-world data. Poster presented at the AMCP Nexus Conference; October 16-19, 2023; Orlando, FL.

8. Massironi S, Cavalcoli F, Rausa E, Invernizzi P, Braga M, Vecchi M. Understanding short bowel syndrome: current status and future perspectives. Dig Liver Dis. 2020;52(3):253-261. doi:10.1016/j.did.2019.11.013

9. Wang CY, Liu S, Xie XN, Tan ZR. Regulation profile of the intestinal peptide transporter 1 (PepT1). Drug Des Devel Ther. 2017;11:3511-3517. Published 2017 Dec 8. doi:10.2147/DDDT.S151725

10. Data on file. SBS patient insights program: digital ethnography study report. Trinity, LLC. August 16, 2023.

11. Nightingale J, Woodward JM; Small Bowel and Nutrition Committee of the British Society of Gastroenterology. Guidelines for management of patients with a short bowel. Gut. 2006;55(suppl 4):iv1-iv12. doi:10.1136/gut.2006.091108

12. Parrish CR, DiBaise JK. Managing the adult patient with short bowel syndrome. Gastroenterol Hepatol. 2017;13(10):600-608.

13. Muff JL, Sokolovski F, Walsh-Korb Z, et al. Surgical treatment of short bowel syndrome-the past, the present and the future, a descriptive review of the literature. Children (Basel). 2022;9(7):1024. Published 2022 Jul 10. doi:10.3390/children9071024

14. Sudan D, Rege A. Update on surgical therapies for intestinal failure. Curr Opin Organ Transplant. 2014 Jun;19(3):267-275. doi:10.1097/MOT.0000000000000076

15. Ballinger R, Macey J, Lloyd A, et al. Measurement of utilities associated with parenteral support requirement in patients with short bowel syndrome and intestinal failure. Clin Ther. 2018;40(11):1878-1893.e1. doi:10.1016/j.clinthera.2018.09.009

16. Jeppesen PB, Shahraz S, Hopkins T, Worsfold A, Genestin E. Impact of intestinal failure and parenteral support on adult patients with short-bowel syndrome: a multinational, noninterventional, cross-sectional survey. JPEN J Parenter Enteral Nutr. 2022;46(7):1650-1659. doi:10.1002/jpen.2372

17. Winkler MF, Smith CE. Clinical, social, and economic impacts of home parenteral nutrition dependence in short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014;38 (suppl 1):32S-37S. doi:10.1177/0148607113517717

18. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132(7):525-532. doi:10.7326/0003-4819-132-7-200004040-00003

19. Lakkasani S, Seth D, Khokhar I, Touza M, Dacosta TJ. Concise review on short bowel syndrome: etiology, pathophysiology, and management. World J Clin Cases. 2022;10(31):11273-11282. doi:10.12998/wjcc.v10.i31.11273

20. Mesenteric ischemia - symptoms and causes. Mayo Clinic. Published June 2, 2023. Accessed April 11, 2024. https://www.mayoclinic.org/diseases-conditions/mesenteric-ischemia/symptoms-causes/syc-20374989

21. Bhutta BS, Fatima R, Aziz M. Radiation enteritis. In: StatPearls. Treasure Island (FL): Updated August 17, 2023. Accessed May 10, 2024. www.ncbi.nlm.nih.gov/books/NBK526032

22. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology. 2006;130(2 suppl 1):S70-S77. doi:10.1053/j.gastro.2005.10.066

23. Ashorobi D, Ameer MA, Fernandez R. Thrombosis. In: StatPearls. Treasure Island (FL): August 8, 2023. Accessed May 10, 2024. https://www.ncbi.nlm.nih.gov/books/NBK538430